GILEAD TESTING NEW HIV DRUGS

Bay Area pharmaceutical company Gilead Sciences Inc. and giant Merck & Co. are testing the first promising class of AIDS medicines in almost three years, treatments that may provide a new weapon against the drug-resistant strains of the deadly virus. After more than a decade of research, the companies will report patient studies of experimental drugs that block integrase, an enzyme that HIV, the AIDS virus, uses to replicate inside the body.
Inside Bay Area